The global biologics contract development and manufacturing organization (CDMO) market was valued at USD 29.53 billion in 2025 and is projected to grow from USD 31.65 billion in 2026 to USD 55.90 billion by 2034, registering a CAGR of 7.37% during the forecast period (2026–2034).
The market is witnessing robust growth owing to the increasing outsourcing of biologics development and manufacturing, rising demand for monoclonal antibodies and biosimilars, expanding biologics pipelines, and growing investments in advanced biomanufacturing technologies. Pharmaceutical and biotechnology companies are increasingly partnering with CDMOs to reduce operational costs, accelerate time-to-market, and leverage specialized manufacturing expertise.
Key Highlights
- Largest Region: North America
- Fastest Growing Region: Asia-Pacific (CAGR of 9.21%)
- Largest Service Segment: Manufacturing Services
- Fastest Growing Service Segment: Manufacturing Services (CAGR of 8.15%)
- Largest Product Segment: Monoclonal Antibodies
- Fastest Growing Product Segment: Cell and Gene Therapies (CAGR of 10.48%)
- Largest End-User Segment: Pharmaceutical Companies
- Fastest Growing End-User Segment: Biotechnology Companies (CAGR of 8.83%)
Market Dynamics
Driver
The rapid expansion of the global biologics pipeline is one of the primary factors driving the biologics CDMO market. Pharmaceutical and biotechnology companies are increasingly focusing on the development of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and advanced therapies to address complex diseases. As biologics manufacturing requires sophisticated infrastructure, regulatory expertise, and specialized technologies, companies are increasingly outsourcing development and production to experienced CDMOs.
Additionally, the growing need to reduce capital investment and improve manufacturing efficiency has accelerated outsourcing across all phases of biologics development. CDMOs provide flexible production capacity, advanced analytical capabilities, process optimization, and regulatory compliance support, enabling clients to shorten development timelines while maintaining product quality.
Restraint
Despite strong market growth, biologics manufacturing remains highly complex and capital intensive. Establishing large-scale biologics production facilities requires significant investments in equipment, cleanroom infrastructure, quality assurance systems, and skilled personnel. Maintaining compliance with stringent global regulatory standards further increases operational complexity and costs for manufacturers.
Supply chain challenges and manufacturing scalability also pose significant barriers. Variability in biologic products, stringent quality control requirements, and potential production delays can affect commercialization timelines, making manufacturing efficiency a critical concern across the industry.
Opportunity
The rapid advancement of cell and gene therapies presents substantial growth opportunities for biologics CDMOs. As the number of innovative therapies entering clinical development continues to increase, demand for specialized manufacturing platforms, viral vector production, and advanced biologics processing capabilities is expected to grow significantly.
Emerging markets also represent attractive opportunities due to increasing investments in biotechnology infrastructure, supportive government initiatives, and expanding pharmaceutical manufacturing capabilities. The adoption of continuous bioprocessing, automation, artificial intelligence, and digital manufacturing technologies is further expected to enhance production efficiency and create new revenue opportunities for CDMO providers.
Top Market Players
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Catalent, Inc.
- Samsung Biologics
- Fujifilm Diosynth Biotechnologies
- WuXi Biologics
- Boehringer Ingelheim BioXcellence
- AGC Biologics
- AbbVie Contract Manufacturing
- Recipharm AB
- Rentschler Biopharma SE
- KBI Biopharma
Market Segmentation
By Service
- Development Services
- Manufacturing Services
By Product
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Cell and Gene Therapies
- Others
By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Unlock Full Report Insights and Strategic Analysis: https://straitsresearch.com/report/biologics-contract-development-and-manufacturing-organization-cdmo-market
Gain access to comprehensive market forecasts, competitive landscape analysis, company profiles, regional insights, emerging investment opportunities, technological advancements, strategic developments, and future industry outlook with the complete Biologics Contract Development and Manufacturing Organization (CDMO) Market report.
About Us
Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights and market research reports.
Contact Us
Email: sales@straitsresearch.com
U.S.: +1 646 905 0080
U.K.: +44 203 695 0070
